Bronchogen is a synthetic short-chain peptide subject to extensive preclinical investigation for its regulatory effects on bronchial epithelial cells and respiratory tissue expression. PX1 Research supplies high-purity, US-manufactured Bronchogen exclusively for laboratory and in vitro research applications, supported by lot-specific analytical verification.
Bronchogen is a synthetic short-chain peptide subject to extensive preclinical investigation for its regulatory effects on bronchial epithelial cells and respiratory tissue expression. PX1 Research supplies high-purity, US-manufactured Bronchogen exclusively for laboratory and in vitro research applications, supported by lot-specific analytical verification.
A professional manufacturer of research-grade Bronchogen provides highly purified, synthetic tetrapeptide material (Ala-Glu-Asp-Leu) backed by lot-specific analytical documentation, including Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) purity testing and Mass Spectrometry (MS) identity verification. Designed strictly for in vitro and preclinical research, high-quality Bronchogen enables investigators to evaluate respiratory tissue bioregulation, cellular proliferation, and gene expression in controlled laboratory environments.
When acquiring research-grade Bronchogen for academic or institutional protocols, verifying chemical integrity and manufacturing consistency is paramount. Commercial suppliers must maintain stringent batch control, providing fully transparent Certificates of Analysis (COAs) for every production run to ensure reproducible experimental outcomes across cell culture and animal model trials.
Bronchogen is a synthetic peptide bioregulator consisting of four amino acids: L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu). Belonging to the class of short-chain peptide bioregulators originally conceptualized in peptide gerontology, its low molecular weight allows it to interact directly with chromatin structures within cell nuclei in experimental models.
In chemical synthesis, maintaining the exact sequence and stereochemistry of Ala-Glu-Asp-Leu is necessary to ensure biological activity in preclinical assays. Standard automated solid-phase peptide synthesis (SPPS) protocols are employed by PX1 Research to yield high-purity sequences free from truncated side-products or racemized derivatives, as detailed in our comprehensive all peptides catalog.
Preclinical investigations demonstrate that short peptide sequences like Bronchogen modulate chromatin conformation by binding to specific DNA sequence motifs in promoter regions of target genes. In bronchial epithelial cell cultures, Bronchogen exposure has been observed to alter histones and alter the expression of proteins involved in cellular repair, mucociliary clearance, and inflammatory cascades.
In vitro data indicate that Bronchogen plays a role in modulating cytokine production under hypoxic or inflammatory stress conditions. Specifically, preclinical models measuring cell viability after exposure to environmental toxins indicate that Bronchogen treatment reduces the overproduction of pro-inflammatory signals such as TNF-alpha and IL-6, while preserving cell monolayer integrity.
Researchers exploring the broad mechanisms of short-chain peptides often examine Bronchogen alongside other synthetic regulatory sequences detailed in our review of Khavinson peptide bioregulators.
To understand the selective target affinity of Bronchogen, laboratory investigators frequently compare its activity profile against other short-chain research peptides. While Bronchogen focuses specifically on pulmonary and bronchial tissue models, compounds like Epitalon target neuroendocrine signaling and telomerase activity, while Thymosin Alpha-1 functions primarily in systemic immune cell differentiation assays.
Furthermore, tissue repair models often evaluate Bronchogen in conjunction with broad-spectrum cytoprotective agents such as BPC-157. Comparative studies help map how organ-specific short peptides alter localized gene expression relative to systemic peptide therapies in organoid and explant models.
For additional technical frameworks on how distinct peptide structures modulate tissue-specific cellular recovery, explore our dedicated portal on pulmonary and respiratory tissue research.
Acquiring reliable research compounds requires evaluating a manufacturer's analytical protocols. Peer-reviewed research depends on consistency; therefore, every lot of Bronchogen manufactured for laboratory use must undergo rigorous physical and chemical characterization.
PX1 Research enforces strict quality assurance metrics across all batch production:
- **Purity Verification by RP-HPLC**: Every lot must demonstrate ≥98% chemical purity via Reversed-Phase High-Performance Liquid Chromatography to ensure non-target peptide fragments do not distort experimental assays.
- **Mass Spectrometry (MS) Identity**: LC-MS testing confirms the exact molecular weight (446.45 g/mol) and structural fragment distribution of the Ala-Glu-Asp-Leu sequence.
- **Endotoxin Analysis**: Endotoxins (lipopolysaccharides) can provoke non-specific immune responses in cell cultures and animal models. All PX1 compounds undergo chromogenic LAL assays to ensure endotoxin levels remain below strictly monitored research limits (<0.5 EU/mg).
- **ISO 17025 & GMP Compliance**: Testing is conducted in ISO 17025-accredited laboratories operating under Good Manufacturing Practice guidelines to guarantee absolute data integrity.
Bronchogen is supplied as a lyophilized (freeze-dried) powder to maximize chemical stability during transport and long-term storage. For optimal preservation, unconstituted vials should be stored at -20°C in a dry, dark environment.
When preparing Bronchogen for in vitro assays, standard aseptic laboratory techniques must be observed. Reconstitution is typically performed using sterile Bacteriostatic Water or phosphate-buffered saline (PBS), depending on the requirements of the biological culture system.
After reconstituting, solutions should be aliquoted into single-use microcentrifuge tubes to avoid repeated freeze-thaw cycles, which can cause peptide bond hydrolysis. Reconstituted liquid aliquots should be refrigerated at 2°C to 8°C and utilized within a designated experimental window.
For detailed laboratory safety protocols, solvent compatibility charts, and buffer preparation guidelines, scientists can access the PX1 Research central repository.
In cell culture research, Bronchogen is utilized to study bronchial epithelial cell differentiation, cilia beating frequency, and goblet cell hyperplasia under stress conditions. Laboratory models introduce Bronchogen to primary human bronchial epithelial cells (HBECs) to measure changes in trans-epithelial electrical resistance (TEER), an indicator of tight junction integrity.
Additional research protocols utilize Bronchogen in oxidative stress models. By exposing cultured lung fibroblasts to hydrogen peroxide or cigarette smoke extract, investigators measure whether Bronchogen administration alters superoxide dismutase (SOD) activity and intracellular ROS accumulation.
These cellular studies help clarify the exact signaling pathways—such as NF-κB downregulation and Nrf2 pathway activation—through which short peptides exert protective effects in preclinical lung tissue models.
Academic institutions, biotechnology enterprises, and contract research organizations (CROs) require dependable supply chains to support multi-phase experimental projects. PX1 Research offers flexible sourcing structures for laboratories requiring consistent, bulk-synthesized peptide lots.
Our US-based manufacturing and distribution hubs in California and Arizona ensure immediate dispatch (same-day shipping Monday through Friday), preventing research delays caused by overseas transit or customs clearance issues. Institutional buyers seeking bulk quantities or custom synthesis runs can establish dedicated accounts via our wholesale research peptide accounts portal.
What is the sequence and molecular weight of Bronchogen?
Bronchogen is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Leu (L-alanyl-L-glutamyl-L-aspartyl-L-leucine) and a molecular weight of approximately 446.45 g/mol.
What is the primary focus of Bronchogen research in preclinical literature?
Preclinical studies focus on Bronchogen's ability to modulate gene expression in bronchial epithelial tissue, reduce pro-inflammatory cytokine production, and maintain cellular monolayer integrity under hypoxic or oxidative stress conditions in vitro.
How is Bronchogen purity verified by PX1 Research?
PX1 Research verifies Bronchogen purity using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to ensure ≥98% purity, alongside Liquid Chromatography-Mass Spectrometry (LC-MS) to verify exact molecular identity.
Why is endotoxin testing critical for research-grade Bronchogen?
Bacterial endotoxins can trigger unintended inflammatory responses in cell cultures and animal models, confounding experimental results. Testing ensures endotoxin levels remain below strictly controlled laboratory thresholds (<0.5 EU/mg).
How should lyophilized Bronchogen be stored in the lab?
Lyophilized Bronchogen should be stored at -20°C in a desiccated environment away from light. Once reconstituted in sterile buffer or water, solutions should be aliquoted and stored at 2°C to 8°C to prevent degradation from freeze-thaw cycles.
Is Bronchogen approved for human use or medical treatment?
No. Bronchogen is supplied strictly as a research compound for in vitro, cell culture, and laboratory animal studies. It is not approved for human consumption, clinical use, diagnosis, or therapeutic applications.
Can Bronchogen be sourced in bulk for institutional research?
Yes, PX1 Research provides bulk sourcing and custom lot sizing for qualified academic and corporate research laboratories through our institutional wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.